How much does one year of treatment with Lapatinib cost approximately

Lapatinib (Lapatinib) is a small molecule targeted drug used to treat HER2-positive advanced or metastatic breast cancer. The cost issue has always been a focus of concern for patients and their families. Since lapatinib is a long-term oral treatment drug, and the treatment course often spans from several months to a year or even longer, the total annual cost will be significantly affected by the brand source, specifications, purchasing channels and local market policies. The core ingredients of lapatinib are consistent globally, but the pricing gap between the original drug and generic drugs is large, resulting in a very obvious gradient in patients' actual expenditures.

From the perspective of the international market, the original drug lapatinib was produced by the original R&D company. After the patent of the product expired, many countries successively launched generic versions. In high-income countries such as Europe and the United States, the original version of lapatinib still maintains a relatively high price and is often among the most expensive in the prescription drug system. The drug may cost tens of thousands of yuan a year. Therefore, most patients in these countries rely on commercial insurance or medical subsidies to share expenses.

Based on the current more common overseas prices, if the original Turkish drug is used, each bottle is usually 70 tablets of 0.25g. The price is about more than 2,000 yuan. If calculated based on the common daily dose of 1,250 mg or 1,500 mg, the treatment cost for one year is about 30,000 to 50,000 yuan. Short-term dose changes when combined with capecitabine, long-term maintenance doses when combined with aromatase inhibitors, etc. may affect the total dosage.

On the other hand, if you choose generic drugs from India or Bangladesh, since a single bottle usually sells for about 600 yuan, the annual treatment cost will be significantly reduced. It is estimated that about 10,000 yuan can cover a year of regular treatment. Although low in price, these generic drugs are usually produced based on the consistency evaluation system of the original drug and are consistent with the international mainstream versions in terms of drug ingredients and dosage specifications, so they are widely used clinically in many countries.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html